RestructuringOct 30, 2026, 05:26 PM
Vistagen Therapeutics Cuts 31% of Workforce, Expects $3.2M Annual Savings
AI Summary
Vistagen Therapeutics, Inc. announced a significant workforce reduction, cutting approximately 31% of its staff. This strategic move is intended to reduce operating expenses, preserve capital through cost efficiencies, and align the company's structure with its late clinical-stage development priorities for key candidates like fasedienol, itruvone, and refisolone. The company estimates incurring approximately $1.0 million in severance and termination costs, while anticipating annual savings of about $3.2 million in salary and benefits.
Key Highlights
- Vistagen Therapeutics reduced workforce by approximately 31% to reduce operating expenses and preserve capital.
- The workforce reduction is expected to save approximately $3.2 million in salary and benefits annually.
- The Company estimates it will incur severance and termination costs of approximately $1.0 million.
- The reduction aims to align workforce with late clinical-stage priorities for fasedienol, itruvone, and refisolone.
Price Impact
More from VTGN